$ENLV

Enlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026; Stock Down

Enlivex Ltd. (ENLV) said it will conduct a 1-for-15 reverse stock split effective July 9, 2026, with shares trading on a split-adjusted basis on Nasdaq. The company expects authorized shares to fall to 158.3M and issued shares to drop to ~16.8M, with proportional adjustments to warrants/options. ENLV closed at $0.51 Monday.

Original reporting
Published Jul 7, 2026, 7:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 7, 2026, 7:07 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$ENLV
Neutral
medium confidence
Mentioned
$ENLV
Relevance
6/10
alphai data visualization · based on rttnews.com
Decision brief

The 30-second read

$ENLVNeutralMed
01

Why it matters

ENLV’s share count and par value will change, and warrants/options exercise prices will be proportionately adjusted; the key tradable element is the effective-date transition to split-adjusted trading.

02

Market read

This is a concrete corporate-action timeline with mechanical share/strike adjustments, which can drive short-term trading volatility and require position/derivative contract recalibration.

03

What to watch

Traders should focus on how the split-adjusted price affects technical levels, options/warrant strike adjustments, and any Nasdaq compliance or financing expectations not detailed in the article.

Relevance 6/10Novelty 6/10Timing: Effective July 9, 2026; trading begins on a split-adjusted basis that day.

Background

Reverse stock splits consolidate shares to raise the per-share trading price; they are often used by smaller issuers for listing-price optics or capital-structure management.

Company-level read

Ticker impact

$ENLVNeutralMedium confidence
Context

Enlivex announces a 1-for-15 reverse stock split effective July 9, 2026, with issued shares dropping to ~16.8M and warrants/options adjusted.

Expected impact

Likely short-term volatility around the effective date, with price levels mechanically reset on a split-adjusted basis.

Evidence & confidence

The article provides the split ratio, effective date, and share-count/warrant adjustment mechanics; it does not cite new operating fundamentals, so directional impact is uncertain.

Market effects

Limited direct read-across; reverse splits are company-specific but can influence microcap sentiment and liquidity conditions.

Primarily impacts Nasdaq-listed microcap trading flows; no broader regional linkage stated.

Low; the event is specific to Enlivex and does not describe global supply/demand or regulatory changes.

Counterpoint

Because the reverse split does not change ownership percentages or voting rights, the long-term value impact may be minimal absent new fundamentals; the move may be mostly mechanical.

Key entities

  • Enlivex Ltd.

    Nasdaq-listed company implementing a 1-for-15 reverse stock split effective July 9, 2026.

  • Nasdaq Capital Market

    Trading venue where ENLV will begin trading on a split-adjusted basis on the effective date.

Related articles

$ENLVMed

FDA Grants Allocetra RMAT Designation for Knee Osteoarthritis

Enlivex Ltd. (Nasdaq: ENLV) said its management will host a July 30, 2026 investor webinar covering a recently announced private placement, its Rain protocol-based RAIN treasury strategy, and clinical progress for Allocetra. Enlivex also reported the FDA granted Allocetra RMAT designation for symptomatic knee osteoarthritis in patients aged 64+.

$ENLVMedAI 8/10

Enlivex's Allocetra Secures FDA RMAT Designation For Knee Osteoarthritis Treatment

Enlivex Ltd. (ENLV) said the FDA granted RMAT designation to its Allocetra therapy for age-related symptomatic knee osteoarthritis in older adults. The RMAT decision cites results from its completed Phase I/IIa trial showing statistically significant improvements in pain and function vs placebo, durable to six months. Enlivex is starting a Phase IIb trial enrolling 182 patients and plans an FDA Type B meeting.

$ENLVMedAI 8/10

Exclusive: FDA grants RMAT designation to Enlivex’s Allocetra for knee OA By Investing.com

Investing.com reports the FDA granted RMAT designation to Enlivex’s experimental immunotherapy Allocetra for age-related knee osteoarthritis in patients 64+. The status may enable more frequent early FDA interactions and could support accelerated approval. Enlivex is running a Phase IIb trial to enroll 182 patients, with first U.S. dosing done and topline data expected by end of Q2 2027.

$PDDMedAI 8/10

Housing, Employment Numbers Featured in Short Week in U.S.

The article previews a short U.S. and Canada market week after Memorial Day, highlighting housing, confidence, jobs, and earnings. It lists U.S. EPS results for PDD, AutoZone, Elbit, Salesforce, Synopsys, Marvell, Costco, Dell, and Autodesk, plus Canada banks’ and other firms’ EPS. Key data include S&P Case-Shiller (March), jobless claims and durable goods (May 23/April), and Canada payroll employment and GDP.

$IMTXHighAI 9/10

Immatics Announces $150 Million Underwritten Offering; Stock Up

Immatics N.V. (IMTX) plans to raise $150 million through a public offering, selling 12.95 million shares at $8.69 each and warrants for 4.32 million shares. The offering is expected to close August 26, 2026, with underwriters having a 30-day option to buy additional shares. IMTX stock is up 10.82% in pre-market trading.